Home/Filings/4/0001610717-24-000492
4//SEC Filing

Chapman Gina 4

Accession 0001610717-24-000492

CIK 0001966494other

Filed

Sep 19, 8:00 PM ET

Accepted

Sep 20, 5:24 PM ET

Size

14.2 KB

Accession

0001610717-24-000492

Insider Transaction Report

Form 4
Period: 2024-09-18
Chapman Gina
DirectorPresident & CEO
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-09-192,975549,515 total
    Exercise: $5.03Exp: 2033-04-20Common Stock (2,975 underlying)
  • Sale

    Common Stock

    2024-09-19$25.03/sh2,975$74,457103,905 total
  • Exercise/Conversion

    Common Stock

    2024-09-18$5.03/sh+7,166$36,045111,071 total
  • Exercise/Conversion

    Common Stock

    2024-09-19$5.03/sh+2,975$14,964106,880 total
  • Sale

    Common Stock

    2024-09-18$25.09/sh7,166$179,775103,905 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-09-187,166552,490 total
    Exercise: $5.03Exp: 2033-04-20Common Stock (7,166 underlying)
Footnotes (4)
  • [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 25, 2024.
  • [F2]This transaction was executed in multiple trades in prices ranging from $25.00 to $25.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F3]This transaction was executed in multiple trades in prices ranging from $25.00 to $25.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F4]25% of the shares subject to the option vest on the first anniversary measured from February 9, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Documents

1 file

Issuer

CARGO Therapeutics, Inc.

CIK 0001966494

Entity typeother

Related Parties

1
  • filerCIK 0001989220

Filing Metadata

Form type
4
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 5:24 PM ET
Size
14.2 KB